Floatz logo

ONDANSETRON

Lymphoma

Fox Chase Cancer CenterSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
65/ 100

Competitive context

287 Active assets in the Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
Cyclophosphamide
Beth Israel Deaconess Medical Center
Phase 4BB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

ONDANSETRON is also rated in:

cancer of unknown primary siteDormant
BB
Indicative · Phase 3
71 / 100
View asset →
childhood neoplasmDormant
BB
Indicative · Phase 3
66 / 100
View asset →
alcohol abuseDormant
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →